science wire

« BACK

Pharmacology



Results 251 - 300 of 1314.


Health - Pharmacology - 20.10.2018
Roche’s Tecentriq in combination with Abraxane improves outcomes as an initial treatment for people with PD-L1-positive metastatic triple-negative breast cancer
Tecentriq combination first immunotherapy regimen to demonstrate positive Phase III results in breast cancer Tecentriq and nab -paclitaxel significantly reduced the risk of disease worsening or death in both the intention-to-treat and PD-L1-positive populations Clinically meaningful overall survival improvement in the PD-L1-positive population at this interim analysis Data are being presented at the European Society for Medical Oncology (ESMO) 2

Health - Pharmacology - 19.10.2018
Novartis phase II GEOMETRY mono-1 trial of investigational medicine capmatinib (INC280) shows positive results in patients with MET mutated advanced NSCLC
Novartis phase II GEOMETRY mono-1 trial of investigational medicine capmatinib (INC280) shows positive results in patients with MET mutated advanced NSCLC Phase II study efficacy data showed overall response rate of 72.0% and 39.1%, respectively, in treatment-naive and previously treated patients with advanced MET exon-14 skipping mutated non-small cell lung cancer (NSCLC)   Clinical findings from ongoing study indicate safety prof

Pharmacology - Health - 19.10.2018
Novartis announces presentation of new Lutathera NETTER-1 data
Novartis announces presentation of new Lutathera NETTER-1 data at ESMO demonstrating significant improvement in PFS regardless of baseline liver tumor burden Lutathera treatment was associated with a

Pharmacology - Health - 18.10.2018

Pharmacology - Health - 16.10.2018
Novartis 5-year data in psoriatic arthritis and ankylosing spondylitis reinforces Cosentyx leadership in spondyloarthritis
Data from the MEASURE 1 and FUTURE 1 studies show rapid and long-lasting sustained improvement in the signs and symptoms of ankylosing spondylitis (AS) and psoriatic arthritis (PsA) ,   In rheumatolo

Health - Pharmacology - 15.10.2018
Roche’s Kadcyla reduced the risk of disease recurring in people with HER2-positive early breast cancer with residual disease after neoadjuvant treatment
Phase III KATHERINE study shows Kadcyla significantly improved invasive disease-free survival compared to Herceptin in people with HER2-positive early breast cancer with residual disease after neoadjuvant treatment Data will be submitted to health authorities around the world, including the US Food and Drug Administration and European Medicines Agency Results will be presented at the 2018 San Antonio Breast Cancer Symposium in December Roche tod

Pharmacology - Health - 10.10.2018
Novartis announces new data from the first direct head-to-head trial to demonstrate superior efficacy of Gilenya over Copaxone in patients with relapsing remitting multiple sclerosis
Topline findings from ASSESS show adult relapsing remitting multiple sclerosis (RRMS) patients taking Gilenya (fingolimod) 0.5mg experienced significantly fewer relapses than patients on Copaxone (glatiramer acetate) 20mg   Gilenya 0.5mg is the first and only disease modifying therapy to show superiority in reducing relapses vs Copaxone in a controlled, head-to-head trial   Treatment discontinuations were overall more common in the

Health - Pharmacology - 09.10.2018
Novartis analysis shows crizanlizumab (SEG101) increased the number of patients free of sickle cell pain crises vs placebo during SUSTAIN study
Novartis analysis shows crizanlizumab (SEG101) increased the number of patients free of sickle cell pain crises vs placebo during SUSTAIN study Data published in the American Journal of Hematology show more than twice as many patients taking crizanlizumab did not experience a disease-related pain crisis (also called vaso-occlusive crisis, or VOC) vs placebo   VOCs are the most common, painful complication of sickle cell disease and the main reas

Pharmacology - Health - 08.10.2018
Novartis announces FDA and EMA filing acceptance of siponimod, the first and only drug shown to meaningfully delay disability progression in typical SPMS patients
There is a critical need for safe and effective treatments for secondary progressive multiple sclerosis (SPMS) - a highly debilitating form of MS characterized by gradual, irreversible worsening of d

Pharmacology - Health - 04.10.2018
FDA approves Roche’s Hemlibra for haemophilia A without factor VIII inhibitors
First medicine to significantly reduce treated bleeds compared to prior factor VIII prophylaxis based on an intra-patient comparison Only medicine that can be self-administered subcutaneously once we

Health - Pharmacology - 04.10.2018
Positive phase III results for baloxavir marboxil in people at high risk of complications from influenza to be presented at IDWeek 2018
Baloxavir marboxil - a first-in-class, single-dose, investigational oral medicine - is the first potential influenza treatment in clinical trials to demonstrate a clinically meaningful benefit for people highly vulnerable to serious influenza complications CAPSTONE-2 showed that baloxavir marboxil significantly reduced time to improvement of influenza symptoms versus placebo Influenza, or ‘flu', results in millions of debilitating illnesse

Health - Pharmacology - 04.10.2018
Sandoz Healthcare Access Challenge (HACk) returns, seeking digital solutions to local healthcare access challenges
Despite major advances in modern medicine, universal access to healthcare remains the largest unmet medical need Building on the inaugural Sandoz HACk, this year's competition expands to seek broader

Health - Pharmacology - 03.10.2018
Roche announces new data for risdiplam in Spinal Muscular Atrophy (SMA) at the World Muscle Society Congress
Roche announces new data for risdiplam in Spinal Muscular Atrophy (SMA) at the World Muscle Society Congress Preliminary findings from Part 1 of the FIREFISH study show that infants with Type 1 SMA are meeting developmental milestones including sitting without support Preliminary data from Part 1 of the SUNFISH study show improvements in motor function in people with Type 2/3 SMA No drug-related safety findings leading to withdrawal in risdiplam

Health - Pharmacology - 03.10.2018
Novartis licenses three novel anti-infective programs to Boston Pharmaceuticals
Clinical and pre-clinical stage programs focused on addressing growing need for new treatments against drug resistant Gram-negative bacteria   Agreement is part of Novartis strategy to partner with l

Health - Pharmacology - 24.09.2018
Roche’s investigational medicine entrectinib showed a durable response of more than two years in people with a specific type of lung cancer
Entrectinib reduced tumours in people with ROS1-positive non-small cell lung cancer (NSCLC), including those whose disease had spread to the central nervous system (CNS) Data will be submitted to glo

Health - Pharmacology - 24.09.2018
Roche announces global availability of blood-based genomic profiling test, FoundationOne Liquid
Liquid biopsy test can identify 70 of the most commonly mutated genes in solid tumours, as well as microsatellite instability Many cancer patients have insufficient or inadequate tissue for genomic t

Pharmacology - Health - 18.09.2018
Roche’s NAVIFY decision support portfolio unlocks relevant content from clinical trial and medical publication databases
Roche launches an app ecosystem with the first two clinical decision support apps The apps query globally-renowned resources based on real-world data Patient-specific results lead to more personalise

Health - Pharmacology - 13.09.2018

Pharmacology - Health - 13.09.2018
Novartis announces NEJM publication of landmark PARADIGMS study demonstrating significant benefit of Gilenya in children and adolescents with MS
Treatment with Gilenya (fingolimod) substantially reduced the debilitating impact of MS, with significant decreases in key measures of disease activity vs.

Health - Pharmacology - 13.09.2018
Novartis real-world evidence confirms efficacy and safety benefits of Cosentyx in daily life for psoriasis patients
Real-world evidence confirms Cosentyx efficacy and safety consistent with previously reported clinical studies - Novartis presents a large program of real-world evidence at the 27 th European Academy of Dermatology and Venereology (EADV) Congress, adding to the robust body of clinical data supporting the use of Cosentyx in moderate-to-severe psoriasis - Cosentyx 5-year data in psoriasis from a Phase III study were presented in 2017 , proving lon

Health - Pharmacology - 12.09.2018
Novartis survey shows psoriasis patients want treatment effect beyond clear skin
New patient preference survey confirms that patients value clear skin the most, but expect additional benefits from their treatment, such as proven long-term efficacy and safety data and no injection site reactions A separate ranking incorporating additional characteristics showed that effectiveness in treating multiple manifestations of psoriatic disease was also important The number of injections per dose and injection frequency were least imp

Health - Pharmacology - 10.09.2018
How medicine literally gets under your skin
How medicine literally gets under your skin
If drugs are to enter the body painlessly and efficiently, they can be administered via skin patches.

Pharmacology - Life Sciences - 07.09.2018
Using biosensors to deliver personalized doses of antibiotics
A team of eight EPFL students won the technical prize in the SensUs international competition, designing a portable biosensor that can measure the amount of vancomycin in a patient's blood stream, enabling doctors to better control the dosage and reduce harmful side effects.

Health - Pharmacology - 06.09.2018
Roche to present new data from its extensive lung cancer programme at the 2018 World Conference on Lung Cancer (WCLC)
Roche to present new data from its extensive lung cancer programme at the 2018 World Conference on Lung Cancer (WCLC) New and updated pivotal data from the TECENTRIQ lung programme, including overall

Health - Pharmacology - 29.08.2018
European Commission approves Novartis combination therapy Tafinlar + Mekinist for adjuvant treatment of BRAF V600 mutation-positive melanoma
Approval based on COMBI-AD study demonstrating greater than 50% reduction in risk of disease recurrence or death in stage III melanoma patients    More than 50% of stage III melanoma patients are lik

Health - Pharmacology - 27.08.2018
Novartis receives European Commission approval of its CAR-T cell therapy, Kymriah (tisagenlecleucel)
The EC approval is based on the first global CAR-T registration trials, which included patients from eight European countries and demonstrated durable responses and a consistent safety profile in r/r

Pharmacology - Health - 20.08.2018
China National Drug Administration grants rapid approval of Roche’s Alecensa (alectinib) as a treatment for ALK-positive lung cancer
China National Drug Administration grants rapid approval of Roche's Alecensa (alectinib) as a treatment for ALK-positive lung cancer Approval follows priority review of Alecensa in China, just eight

Health - Pharmacology - 03.08.2018
PRIME designation granted by European Medicines Agency for RG6042 for treatment of Huntington’s disease
European Medicines Agency PRIME (PRIority MEdicines) status is granted to medicines that may offer a major therapeutic advantage over existing treatments, or benefit patients without treatment options RG6042 has the potential to be the first therapy targeting the underlying cause of Huntington's disease, a fatal neurodegenerative rare disease Third PRIME designation for a Roche medicine Roche today announced that the European Medicines Agency (E

Health - Pharmacology - 31.07.2018

Pharmacology - Health - 30.07.2018
Novartis marks a new era for migraine patients with the EU approval of Aimovig , a first-of-its-kind treatment specifically designed for migraine prevention
Novartis marks a new era for migraine patients with the EU approval of Aimovig , a first-of-its-kind treatment specifically designed for migraine prevention Patients on Aimovig (erenumab) in clinical

Health - Pharmacology - 27.07.2018
Novartis combination Tafinlar + Mekinist receives positive CHMP opinion for adjuvant treatment of BRAF V600 mutation-positive melanoma
Phase III trial showed a 53% reduction in risk of recurrence or death with the combination of a BRAF and MEK inhibitor as adjuvant therapy versus placebo   Relapse-free survival benefit with Tafinlar

Health - Pharmacology - 23.07.2018
Novartis renews drug donation of Egaten (triclabendazole) until 2022, reaffirming its commitment to the fight against liver fluke
Novartis extends agreement with the WHO for the donation of Egaten for the treatment of liver fluke, a neglected tropical disease, also known as fascioliasis, that infects more than 2.4 millio

Pharmacology - Health - 20.07.2018
Roche to present new data demonstrating the breadth and depth of its Alzheimer’s programme at the upcoming Alzheimer’s Association International Conference
Roche to present new data demonstrating the breadth and depth of its Alzheimer's programme at the upcoming Alzheimer's Association International Conference Late-breaking Phase II exploratory analysis

Health - Pharmacology - 20.07.2018
FDA grants Breakthrough Device Designation for Roche’s Elecsys cerebrospinal fluid (CSF) assays to support the improved diagnosis of Alzheimer’s disease
FDA grants Breakthrough Device Designation for Roche's Elecsys cerebrospinal fluid (CSF) assays to support the improved diagnosis of Alzheimer's disease Roche announced today, that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to Elecsys ß-Amyloid (1-42) CSF and Elecsys Phospho-Tau (181P) CSF.

Pharmacology - Health - 19.07.2018
Roche’s Tecentriq in combination with pemetrexed and platinum-based chemotherapy reduced the risk of disease worsening or death in the initial treatment of people with advanced lung cancer
Roche today announced that the Phase III IMpower132 study met its co-primary endpoint of progression-free survival (PFS) and demonstrated that the combination of Tecentriq (atezolizumab) plus chemoth

Health - Pharmacology - 18.07.2018
Novartis Kisqali now first and only CDK4/6 inhibitor indicated in US as first-line therapy specifically for premenopausal women; and as initial therapy with fulvestrant in postmenopausal women
Novartis Kisqali now first and only CDK4/6 inhibitor indicated in US as first-line therapy specifically for premenopausal women; and as initial therapy with fulvestrant in postmenopausal women Kisqal

Pharmacology - Business / Economics - 18.07.2018
Novartis delivers solid growth in second quarter and continues transformation to a focused medicines company
Net sales grew 5% (cc , +7% USD) mainly driven by: Cosentyx grew to USD 701 million, (+40% cc) with strong growth in all indications in the US and EU Entresto sales more than doubled to USD 239 millio

Pharmacology - Health - 18.07.2018
FDA grants Breakthrough Therapy Designation for Roche’s Tecentriq in combination with Avastin as first-line treatment for advanced or metastatic hepatocellular carcinoma (HCC)
FDA grants Breakthrough Therapy Designation for Roche's Tecentriq in combination with Avastin as first-line treatment for advanced or metastatic hepatocellular carcinoma (HCC) Roche today announced t

Health - Pharmacology - 02.07.2018
Roche commences tender offer for all shares of Foundation Medicine, Inc. for US$ 137.00 per share in cash
Roche today announced that it has commenced a cash tender offer for all of the outstanding shares of common stock of Foundation Medicine, Inc.

Health - Pharmacology - 02.07.2018
Phase III IMpassion130 study showed Roche’s Tecentriq plus Abraxane significantly reduced the risk of disease worsening or death in people with metastatic triple negative breast cancer
First Phase III immunotherapy study to demonstrate a statistically significant improvement in progression-free survival (PFS) in the intention-to-treat (ITT) and PD-L1 positive first-line metastatic